Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy

Farshid Dayyani, Hagop Kantarjian, Susan O'Brien, Sherry Pierce, Dan Jones, Stefan Faderl, Guillermo Garcia-Manero, Jorge Cortes, Farhad Ravandi

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Patients with therapy-related acute promyelocytic leukemia (t-APL) have been commonly exposed to topoisomerase inhibitors and may potentially benefit from induction regimens omitting anthracyclines. METHODS: Retrospective analysis of the outcomes of 29 patients with t-APL who were either treated with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) or with standard ATRA plus anthracycline-based chemotherapy was performed. RESULTS: Prior therapy included chemotherapy alone, radiation alone, or a combination of the 2 in 19%, 33%, and 47% of patients, respectively. The combination of ATO and ATRA (n = 19) for induction resulted in a similar remission rate compared with ATRA plus chemotherapy (n = 10) (89% vs 70%; P =.35). The median overall survival for the patients treated with ATRA plus ATO was not reached compared with that for patients treated with ATRA plus chemotherapy (161 weeks; P =.79). CONCLUSIONS: In this cohort of t-APL patients, outcomes with ATO and ATRA appeared to be comparable to anthracycline-containing induction regimens. This combination may be preferable in t-APL patients to avoid any risk of anthracycline-induced toxicities. Cancer 2011.

Original languageEnglish (US)
Pages (from-to)110-115
Number of pages6
JournalCancer
Volume117
Issue number1
DOIs
StatePublished - Jan 1 2011
Externally publishedYes

Fingerprint

Acute Promyelocytic Leukemia
Tretinoin
Anthracyclines
Drug Therapy
Therapeutics
Topoisomerase Inhibitors
arsenic trioxide
Radiation
Survival

Keywords

  • all-trans-retinoic acid
  • arsenic trioxide
  • outcome
  • therapy-related acute promyelocytic leukemia

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Dayyani, F., Kantarjian, H., O'Brien, S., Pierce, S., Jones, D., Faderl, S., ... Ravandi, F. (2011). Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy. Cancer, 117(1), 110-115. https://doi.org/10.1002/cncr.25585

Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy. / Dayyani, Farshid; Kantarjian, Hagop; O'Brien, Susan; Pierce, Sherry; Jones, Dan; Faderl, Stefan; Garcia-Manero, Guillermo; Cortes, Jorge; Ravandi, Farhad.

In: Cancer, Vol. 117, No. 1, 01.01.2011, p. 110-115.

Research output: Contribution to journalArticle

Dayyani, F, Kantarjian, H, O'Brien, S, Pierce, S, Jones, D, Faderl, S, Garcia-Manero, G, Cortes, J & Ravandi, F 2011, 'Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy', Cancer, vol. 117, no. 1, pp. 110-115. https://doi.org/10.1002/cncr.25585
Dayyani, Farshid ; Kantarjian, Hagop ; O'Brien, Susan ; Pierce, Sherry ; Jones, Dan ; Faderl, Stefan ; Garcia-Manero, Guillermo ; Cortes, Jorge ; Ravandi, Farhad. / Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy. In: Cancer. 2011 ; Vol. 117, No. 1. pp. 110-115.
@article{c1c663a50e044342b730cc5f9a991dc2,
title = "Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy",
abstract = "BACKGROUND: Patients with therapy-related acute promyelocytic leukemia (t-APL) have been commonly exposed to topoisomerase inhibitors and may potentially benefit from induction regimens omitting anthracyclines. METHODS: Retrospective analysis of the outcomes of 29 patients with t-APL who were either treated with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) or with standard ATRA plus anthracycline-based chemotherapy was performed. RESULTS: Prior therapy included chemotherapy alone, radiation alone, or a combination of the 2 in 19{\%}, 33{\%}, and 47{\%} of patients, respectively. The combination of ATO and ATRA (n = 19) for induction resulted in a similar remission rate compared with ATRA plus chemotherapy (n = 10) (89{\%} vs 70{\%}; P =.35). The median overall survival for the patients treated with ATRA plus ATO was not reached compared with that for patients treated with ATRA plus chemotherapy (161 weeks; P =.79). CONCLUSIONS: In this cohort of t-APL patients, outcomes with ATO and ATRA appeared to be comparable to anthracycline-containing induction regimens. This combination may be preferable in t-APL patients to avoid any risk of anthracycline-induced toxicities. Cancer 2011.",
keywords = "all-trans-retinoic acid, arsenic trioxide, outcome, therapy-related acute promyelocytic leukemia",
author = "Farshid Dayyani and Hagop Kantarjian and Susan O'Brien and Sherry Pierce and Dan Jones and Stefan Faderl and Guillermo Garcia-Manero and Jorge Cortes and Farhad Ravandi",
year = "2011",
month = "1",
day = "1",
doi = "10.1002/cncr.25585",
language = "English (US)",
volume = "117",
pages = "110--115",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy

AU - Dayyani, Farshid

AU - Kantarjian, Hagop

AU - O'Brien, Susan

AU - Pierce, Sherry

AU - Jones, Dan

AU - Faderl, Stefan

AU - Garcia-Manero, Guillermo

AU - Cortes, Jorge

AU - Ravandi, Farhad

PY - 2011/1/1

Y1 - 2011/1/1

N2 - BACKGROUND: Patients with therapy-related acute promyelocytic leukemia (t-APL) have been commonly exposed to topoisomerase inhibitors and may potentially benefit from induction regimens omitting anthracyclines. METHODS: Retrospective analysis of the outcomes of 29 patients with t-APL who were either treated with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) or with standard ATRA plus anthracycline-based chemotherapy was performed. RESULTS: Prior therapy included chemotherapy alone, radiation alone, or a combination of the 2 in 19%, 33%, and 47% of patients, respectively. The combination of ATO and ATRA (n = 19) for induction resulted in a similar remission rate compared with ATRA plus chemotherapy (n = 10) (89% vs 70%; P =.35). The median overall survival for the patients treated with ATRA plus ATO was not reached compared with that for patients treated with ATRA plus chemotherapy (161 weeks; P =.79). CONCLUSIONS: In this cohort of t-APL patients, outcomes with ATO and ATRA appeared to be comparable to anthracycline-containing induction regimens. This combination may be preferable in t-APL patients to avoid any risk of anthracycline-induced toxicities. Cancer 2011.

AB - BACKGROUND: Patients with therapy-related acute promyelocytic leukemia (t-APL) have been commonly exposed to topoisomerase inhibitors and may potentially benefit from induction regimens omitting anthracyclines. METHODS: Retrospective analysis of the outcomes of 29 patients with t-APL who were either treated with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) or with standard ATRA plus anthracycline-based chemotherapy was performed. RESULTS: Prior therapy included chemotherapy alone, radiation alone, or a combination of the 2 in 19%, 33%, and 47% of patients, respectively. The combination of ATO and ATRA (n = 19) for induction resulted in a similar remission rate compared with ATRA plus chemotherapy (n = 10) (89% vs 70%; P =.35). The median overall survival for the patients treated with ATRA plus ATO was not reached compared with that for patients treated with ATRA plus chemotherapy (161 weeks; P =.79). CONCLUSIONS: In this cohort of t-APL patients, outcomes with ATO and ATRA appeared to be comparable to anthracycline-containing induction regimens. This combination may be preferable in t-APL patients to avoid any risk of anthracycline-induced toxicities. Cancer 2011.

KW - all-trans-retinoic acid

KW - arsenic trioxide

KW - outcome

KW - therapy-related acute promyelocytic leukemia

UR - http://www.scopus.com/inward/record.url?scp=78650713408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650713408&partnerID=8YFLogxK

U2 - 10.1002/cncr.25585

DO - 10.1002/cncr.25585

M3 - Article

C2 - 20803607

AN - SCOPUS:78650713408

VL - 117

SP - 110

EP - 115

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1

ER -